CA2995580C - Appareil et procede permettant de reduire la tension intraoculaire - Google Patents
Appareil et procede permettant de reduire la tension intraoculaire Download PDFInfo
- Publication number
- CA2995580C CA2995580C CA2995580A CA2995580A CA2995580C CA 2995580 C CA2995580 C CA 2995580C CA 2995580 A CA2995580 A CA 2995580A CA 2995580 A CA2995580 A CA 2995580A CA 2995580 C CA2995580 C CA 2995580C
- Authority
- CA
- Canada
- Prior art keywords
- control device
- flow control
- flow
- housing
- aqueous humor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004410 intraocular pressure Effects 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 53
- 210000001742 aqueous humor Anatomy 0.000 claims abstract description 138
- 238000004891 communication Methods 0.000 claims abstract description 90
- 239000012530 fluid Substances 0.000 claims abstract description 77
- 210000002159 anterior chamber Anatomy 0.000 claims abstract description 66
- 230000004044 response Effects 0.000 claims abstract description 26
- 230000007423 decrease Effects 0.000 claims abstract description 23
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims description 28
- 239000000356 contaminant Substances 0.000 claims description 24
- 210000004087 cornea Anatomy 0.000 claims description 18
- 210000000744 eyelid Anatomy 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 229920001296 polysiloxane Polymers 0.000 claims description 6
- 239000000560 biocompatible material Substances 0.000 claims description 5
- 229920002635 polyurethane Polymers 0.000 claims description 5
- 239000004814 polyurethane Substances 0.000 claims description 5
- 238000004873 anchoring Methods 0.000 claims description 4
- 238000000576 coating method Methods 0.000 description 18
- 210000003786 sclera Anatomy 0.000 description 17
- -1 for example Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 11
- 210000000795 conjunctiva Anatomy 0.000 description 11
- 239000011148 porous material Substances 0.000 description 8
- 230000010339 dilation Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000010412 Glaucoma Diseases 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 230000004509 aqueous humor production Effects 0.000 description 3
- 208000002352 blister Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000003717 douglas' pouch Anatomy 0.000 description 3
- 230000004406 elevated intraocular pressure Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000004424 eye movement Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940117986 sulfobetaine Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- VRBFTYUMFJWSJY-UHFFFAOYSA-N 28804-46-8 Chemical compound ClC1CC(C=C2)=CC=C2C(Cl)CC2=CC=C1C=C2 VRBFTYUMFJWSJY-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024304 Choroidal Effusions Diseases 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 206010010716 Conjunctival erosion Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000007950 Ocular Hypotension Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940123361 Quorum sensing inhibitor Drugs 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 239000002519 antifouling agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 108010089057 melimine Proteins 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000636 poly(norbornene) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001692 polycarbonate urethane Polymers 0.000 description 1
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920005591 polysilicon Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
La présente invention concerne un appareil permettant de réduire/stabiliser la tension intraoculaire. Un tube s'étend à partir d'une extrémité d'entrée en communication fluidique avec une chambre antérieure de l'il, pour diriger un écoulement de l'humeur aqueuse de la chambre antérieure vers une extrémité de sortie en communication fluidique avec une cavité, définie par un logement, permettant de recevoir l'humeur aqueuse. Un dispositif de régulation d'écoulement est mis en prise de manière fonctionnelle avec le logement, et est configuré pour réguler l'écoulement de l'humeur aqueuse, par l'intermédiaire d'un conduit défini par celui-ci et s'étendant de la cavité à un emplacement éloigné de la chambre antérieure. Le conduit peut être dilaté en réponse à la tension intraoculaire étant au-dessus d'une tension présélectionnée, pour augmenter l'écoulement ou pour diminuer la résistance à l'écoulement de l'humeur aqueuse à travers le conduit vers le site de drainage et pour réduire la tension intraoculaire à une valeur inférieure ou égale à la pression présélectionnée. La présente invention concerne également des appareils et des procédés associés.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/826,866 US10342702B2 (en) | 2014-08-29 | 2015-08-14 | Apparatus and method for reducing intraocular pressure |
| US14/826,866 | 2015-08-14 | ||
| PCT/US2016/046579 WO2017030902A2 (fr) | 2015-08-14 | 2016-08-11 | Appareil et procédé permettant de réduire la tension intraoculaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2995580A1 CA2995580A1 (fr) | 2017-02-23 |
| CA2995580C true CA2995580C (fr) | 2020-03-31 |
Family
ID=56787701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2995580A Active CA2995580C (fr) | 2015-08-14 | 2016-08-11 | Appareil et procede permettant de reduire la tension intraoculaire |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3334395A2 (fr) |
| JP (1) | JP2018525107A (fr) |
| CN (1) | CN108135739A (fr) |
| CA (1) | CA2995580C (fr) |
| WO (1) | WO2017030902A2 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
| ES2962607T3 (es) | 2015-08-14 | 2024-03-20 | Alcon Inc | Implante ocular con sensor de presión |
| WO2017106517A1 (fr) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Implant vasculaire et système de pose |
| DE102018203424A1 (de) * | 2018-03-07 | 2019-09-12 | Carl Zeiss Meditec Ag | Shunt-Implantat |
| CN112689488B (zh) * | 2018-09-06 | 2024-04-12 | 洛桑联邦理工学院 | 具有弹性膜的用于治疗过量眼内流体的设备 |
| CN116322583B (zh) * | 2020-07-22 | 2024-03-26 | 国立大学医院（新加坡）私人有限公司 | 眼部引流植入物 |
| JP7220688B2 (ja) * | 2020-09-16 | 2023-02-10 | 巨晰光纖股▲ふん▼有限公司 | 眼球排水用分流支持枠 |
| CA3202776A1 (fr) | 2021-01-11 | 2022-07-14 | Wayne A. Noda | Systemes et procedes d'administration viscoelastique |
| US20220313491A1 (en) * | 2021-04-02 | 2022-10-06 | Twenty Twenty Therapeutics Llc | Passive intraocular pressure control and associated systems, devices, and methods |
| CN113974960A (zh) * | 2021-10-21 | 2022-01-28 | 首都医科大学附属北京同仁医院 | 一种分体式房水引流装置 |
| CN114533387A (zh) * | 2022-01-14 | 2022-05-27 | 南京普立蒙医疗科技有限公司 | 一种青光眼治疗用的引流装置及制作方法 |
| KR20240014206A (ko) * | 2022-07-25 | 2024-02-01 | 주식회사 마이크로트 | 복수 개의 채널을 갖는 안질환용 임플란트 장치 및 이의 제조 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4886488A (en) * | 1987-08-06 | 1989-12-12 | White Thomas C | Glaucoma drainage the lacrimal system and method |
| US5171213A (en) * | 1991-08-14 | 1992-12-15 | Price Jr Francis W | Technique for fistulization of the eye and an eye filtration prosthesis useful therefor |
| US20050119737A1 (en) * | 2000-01-12 | 2005-06-02 | Bene Eric A. | Ocular implant and methods for making and using same |
| US7708711B2 (en) * | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
| US6881198B2 (en) * | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
| US20060069340A1 (en) * | 2003-06-16 | 2006-03-30 | Solx, Inc. | Shunt for the treatment of glaucoma |
| US9186274B2 (en) * | 2005-02-23 | 2015-11-17 | Camras Vision Inc. | Method and apparatus for reducing intraocular pressure |
| US9333115B2 (en) * | 2011-12-13 | 2016-05-10 | Alcon Research, Ltd. | Separation of gas and liquid in membrane valves |
| WO2013090231A1 (fr) * | 2011-12-13 | 2013-06-20 | Alcon Research, Ltd. | Systèmes de drainage actifs dotés de soupapes actionnées par pression à double entrée |
| CN104490515A (zh) * | 2014-12-18 | 2015-04-08 | 肖真 | 青光眼阀和青光眼引流装置 |
-
2016
- 2016-08-11 WO PCT/US2016/046579 patent/WO2017030902A2/fr active Application Filing
- 2016-08-11 CN CN201680058955.XA patent/CN108135739A/zh active Pending
- 2016-08-11 EP EP16754612.6A patent/EP3334395A2/fr active Pending
- 2016-08-11 JP JP2018507558A patent/JP2018525107A/ja active Pending
- 2016-08-11 CA CA2995580A patent/CA2995580C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108135739A (zh) | 2018-06-08 |
| CA2995580A1 (fr) | 2017-02-23 |
| JP2018525107A (ja) | 2018-09-06 |
| WO2017030902A2 (fr) | 2017-02-23 |
| WO2017030902A3 (fr) | 2017-06-29 |
| EP3334395A2 (fr) | 2018-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11723804B2 (en) | Device and method for reducing intraocular pressure | |
| US10342702B2 (en) | Apparatus and method for reducing intraocular pressure | |
| CA2995580C (fr) | Appareil et procede permettant de reduire la tension intraoculaire | |
| US10524958B2 (en) | Method and apparatus for reducing intraocular pressure | |
| US6595945B2 (en) | Glaucoma treatment device and method | |
| US20220395397A1 (en) | New ocular device and method for glaucoma treatment | |
| US20190000673A1 (en) | Ocular implants for reduction of intraocular pressure and methods for implanting same | |
| US20080161741A1 (en) | Ocular implant and methods for making and using same | |
| EP2410959A2 (fr) | Dérivations assurant la prise en charge de l'écoulement de l'humeur aqueuse, utilisées pour le traitement du glaucome et caractérisées par des performances chirurgicales améliorées | |
| AU2014280907B2 (en) | Glaucoma shunts with flow management and improved surgical performance | |
| CA2471242A1 (fr) | Dispositif et methode de traitement du glaucome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180213 |